This database contains 137 studies, archived under the term: "Conclusions"
Click here to filter this large number of results.
A study protocol to investigate the management of depression and challenging behaviors associated with dementia in aged care settings
McCabe, Marita P.,
Mellor, David,
Davison, Tanya E.,
Karantzas, Gery,
von Treuer, Kathryn,
O'Connor, Daniel W.
Background: The high occurrence and under-treatment of clinical depression and behavioral and psychological symptoms of dementia (BPSD) within aged care settings is concerning, yet training programs aimed at improving the detection and management of these problems have generally been ineffective. This article presents a study protocol to evaluate a training intervention for facility managers/registered nurses […]
Use of the Tailored Activities Program to reduce neuropsychiatric behaviors in dementia: an Australian protocol for a randomized trial to evaluate its effectiveness
O'Connor, C. M.,
Clemson, L.,
Brodaty, H.,
Jeon, Y. H.,
Mioshi, E.,
Gitlin, L. N.
Background: Behavioral and psychological symptoms of dementia (BPSD) are often considered to be the greatest challenge in dementia care, leading to increased healthcare costs, caregiver burden, and placement into care facilities. With potential for pharmacological intervention to exacerbate behaviors or even lead to mortality, the development and rigorous testing of non-pharmacological interventions is vital. A […]
“Dementia-friendly hospitals: care not crisis”: an educational program designed to improve the care of the hospitalized patient with dementia
Galvin, James E.,
Kuntemeier, Barbara,
Al-Hammadi, Noor,
Germino, Jessica,
Murphy-White, Maggie,
McGillick, Janis
Background: Approximately 3.2 million hospital stays annually involve a person with dementia, leading to higher costs, longer lengths of stay, and poorer outcomes. Older adults with dementia are vulnerable when hospitals are unable to meet their special needs.; Methods: We developed, implemented, and evaluated a training program for 540 individuals at 4 community hospitals. Pretest, […]
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D.,
Bell, J.,
Mancuso, J. Y.,
Kupiec, J. W.,
Sabbagh, M. N.,
van Dyck, C.,
Thomas, R. G.,
Aisen, P. S.
Objective: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).; Methods: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State Examination score 14-26 were randomized to PF-04494700 60 mg/day × 6 days, […]
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
Freund-Levi, Yvonne,
Jedenius, Erik,
Tysen-Bäckström, Ann Christine,
Lärksäter, Marie,
Wahlund, Lars-Olof,
Eriksdotter, Maria
Objective: To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function.; Methods: Using a randomized, controlled and open-blind, one-center trial at an in- and outpatient clinic at a university hospital, we studied 100 adults with probable dementia and NPSD. Participants received galantamine (N = 50, target dose 24 mg) […]
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C.,
MacKinley, J.,
Blair, M.,
Oliver, L. D.,
Jesso, S.,
Tartaglia, M. C.,
Borrie, M.,
Wells, J.,
Dziobek, I.,
Pasternak, S.,
Mitchell, D. G. V.,
Rankin, K.,
Kertesz, A.,
Boxer, A.
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]
Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Farokhnia, Mehdi,
Shafiee Sabet, Mehdi,
Iranpour, Negar,
Gougol, Amirhossein,
Yekehtaz, Habibeh,
Alimardani, Roozbeh,
Farsad, Farzaneh,
Kamalipour, Maryam,
Akhondzadeh, Shahin
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]